Skip to main content

Table 3 Rates of patients in whom FPS-R improved or worsened by more than 0.5 units

From: Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial

Variable

α-galactosidase

placebo

P

(N = 27)

(N = 25)

Pts with difference of FPS-R score < −0.5, n (%)

14

(52%)

8

(32%)

0.15

Pts with difference of FPS-R score > 0.5, n (%)

3

(11%)

6

(24%)

0.22